🔎 Trials Near Me

Home › Major Depressive Disorder › NCT05922878

Study of ALTO-300 in MDD

RecruitingPhase 2

A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder

Who can join

Ages 18 to 70 · All sexes

Full eligibility criteria
Inclusion Criteria:

* Have a diagnosis of moderate to severe major depressive disorder (MDD)
* At Visit 1, currently taking a single SSRI, SNRI, or bupropion for at least 6 weeks with no dose modifications in the past 2 weeks by Visit 2
* Willing to comply with all study assessments and procedures
* Must not be pregnant or breastfeeding at time of enrollment or throughout study

Exclusion Criteria:

* Evidence of unstable medical condition
* Nightly use of sleep medication
* Diagnosed bipolar disorder, psychotic disorder, or dementia
* Current moderate or severe substance use disorder
* Has a history of hypersensitivity or allergic reaction to ALTO-300 or any of its components/excipients
* Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device

About the study

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

What is being tested

Sponsor: Alto Neuroscience · Participants: 321 · Started: Jun 8, 2023

Contact the study team

Official record on ClinicalTrials.gov — NCT05922878

Locations in the U.S.

ArizonaSite 200, Phoenix
Site 187, Yuma
ArkansasSite 193, Rogers
CaliforniaSite 218, Bellflower
Site 217, Glendale
Site 335, Lafayette
Site 209, Los Angeles
Site 219, Mather
Site 194, Mission Viejo
Site 197, Temecula
ColoradoSite 203, Colorado Springs
Site 349, Evergreen
ConnecticutSite 214, Norwalk
FloridaSite 159, Clermont
Site 225, Miami Gardens
Site 190, Miami Lakes
Site 161, Okeechobee
Site 221, Tampa
Site 220, West Palm Beach
GeorgiaSite 224, Savannah
Site 208, Snellville
IdahoSite 119, Boise
IllinoisSite 310, Chicago
MississippiSite 215, Jackson
NevadaSite 344, Las Vegas
New MexicoSite 114, Albuquerque
New YorkSite 192, Staten Island
North CarolinaSite 199, Hickory
OhioSite 202, Cincinnati
OklahomaSite 195, Oklahoma City
PennsylvaniaSite 216, Allentown
Site 350, Media
Site 352, Moosic
TexasSite 347, Fort Worth
Site 353, Plano (Not yet recruiting)
Site 196, Richmond
UtahSite 207, Clinton
VirginiaSite 211, Roanoke

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.